Chengdu-based WestVac Biopharma Co., Ltd announced the inclusion of its recombinant COVID-19 vaccine (Sf9 cells) in the emergency use program in China. It is the first recombinant protein novel coronavirus vaccine produced by the insect cell technology platform approved for emergency use in China.
Vaccine Efficacy and Technology
The data shows that the drug can induce neutralizing antibodies against COVID-19 prototype strains and variants, and on the basis of existing COVID-19 vaccination, the product, as a sequential booster, can obtain a stronger immune response. In terms of preparation technology, it uses internationally advanced production technology to introduce the gene of COVID-19 into insect cells, prepare the S protein of COVID-19, induce the human body to produce antibodies to block virus infection, and has achieved large-scale production. Using insect cells to produce recombinant COVID-19 protein vaccine allows for good protein expression quality and high safety. There are recombinant protein influenza vaccines, cervical cancer vaccines, and others on the market using the said technical route.
Company Background and Platforms
WestVac Biopharma boasts a mature insect cell expressed recombinant protein platform, novel adjuvant platform, bacterial vaccine platform, tumor vaccine platform, and immunotherapy platform.-Fineline Info & Tech
